Home LiteratureArticle Details
PMID: 10678952 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Role of decay-accelerating factor domains and anchorage in internalization of Dr-fimbriated Escherichia coli.

Infection and immunity ·Vol. 68 ·No. 3 ·2000-03-00 ·Pages 1391-9

Selvarangan R, Goluszko P, Popov V, Singhal J, Pham T, Lublin DM, Nowicki S, Nowicki B

Abstract

Dr-fimbriated Escherichia coli capable of invading epithelial cells recognizes human decay-accelerating factor (DAF) as its cellular receptor. The role of extracellular domains and the glycosylphosphatidylinositol anchor of DAF in the process of internalization of Dr(+) E. coli was characterized in a cell-cell interaction model. Binding of Dr(+) E. coli to the short consensus repeat 3 domain of DAF expressed by Chinese hamster ovary cells was critical for internalization to occur. Deletion of short consensus repeat 3 domain or replacement of Ser(165) by Leu in this domain, or the use of a monoclonal antibody to this region abolished internalization. Replacing the glycosylphosphatidylinositol anchor of DAF with the transmembrane anchor of membrane cofactor protein or HLA-B44 resulted in abolition or reduction of internalization respectively. Cells expressing glycosylphosphatidylinositol-anchored DAF but not the transmembrane-anchored DAF internalized Dr(+) E. coli through a glycolipid pathway, since the former cells were more sensitive to inhibition by methyl-beta-cyclodextrin, a sterol-chelating agent. Electron microscopic studies revealed that the intracellular vacuoles containing the internalized Dr(+) E. coli were morphologically distinct between the anchor variants of DAF. The cells expressing glycosylphosphatidylinositol-anchored DAF contained a single bacterium in tight-fitting vacuoles, while the cells expressing transmembrane-anchored DAF contained multiple (two or three) bacteria in spacious phagosomes. This finding suggests that distinct postendocytic events operate in the cells expressing anchor variants of DAF. We provide direct evidence for the DAF-mediated internalization of Dr(+) E. coli and demonstrate the significance of the glycosylphosphatidylinositol anchor, which determines the ability and efficiency of the internalization event.

MeSH Terms
Adhesins, Escherichia coli/physiology Animals CD55 Antigens/physiology CHO Cells Cricetinae Escherichia coli/physiology Fimbriae, Bacterial/physiology Glycosylphosphatidylinositols/physiology Vacuoles/microbiology
Chemicals
Adhesins, Escherichia coli CD55 Antigens Glycosylphosphatidylinositols
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Selvarangan R
Department of Obstetrics & Gynecology, The University of Texas Medical Branch, Galveston, Texas 77555-1062, USA.
Goluszko P
Popov V
Singhal J
Pham T
Lublin D M
Nowicki S
Nowicki B
References (39)
39 references, click to expand
  1. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids.
    J Exp Med. 1987 Mar 1;165(3):848-64 PMID: 2434600
  2. Diffuse-adhering Escherichia coli (DAEC) as a putative cause of diarrhea in Mayan children in Mexico.
    J Infect Dis. 1991 Mar;163(3):507-13 PMID: 1995723
  3. A hemagglutinin of uropathogenic Escherichia coli recognizes the Dr blood group antigen.
    Infect Immun. 1988 May;56(5):1057-60 PMID: 2895740
  4. Presence of the Dr receptor in normal human tissues and its possible role in the pathogenesis of ascending urinary tract infection.
    Am J Pathol. 1988 Oct;133(1):1-4 PMID: 3052090
  5. Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment.
    Ann Intern Med. 1989 Jan 15;110(2):138-50 PMID: 2462391
  6. Molecular epidemiology of adhesin and hemolysin virulence factors among uropathogenic Escherichia coli.
    Infect Immun. 1989 Feb;57(2):303-13 PMID: 2563254
  7. Virulence factors in Escherichia coli urinary tract infection.
    Clin Microbiol Rev. 1991 Jan;4(1):80-128 PMID: 1672263
  8. Urovirulence determinants in Escherichia coli isolates causing first-episode and recurrent cystitis in women.
    J Infect Dis. 1991 Apr;163(4):773-9 PMID: 1672702
  9. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
    J Exp Med. 1991 Jul 1;174(1):35-44 PMID: 1711565
  10. Endocytosis of glycophospholipid-anchored and transmembrane forms of CD4 by different endocytic pathways.
    EMBO J. 1992 Mar;11(3):863-74 PMID: 1532143
  11. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
    J Immunol. 1992 Nov 1;149(9):2906-13 PMID: 1383332
  12. Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant Dr adhesin in a model of a cell-cell interaction.
    J Exp Med. 1993 Dec 1;178(6):2115-21 PMID: 7504058
  13. Viral infection and the pathogenesis of dilated cardiomyopathy.
    Circ Res. 1994 Feb;74(2):182-8 PMID: 8293557
  14. Structure and function of decay accelerating factor CD55.
    J Lab Clin Med. 1994 Apr;123(4):485-91 PMID: 7511675
  15. Complement receptors and regulatory proteins: immune adherence revisited and abuse by microorganisms.
    Clin Exp Immunol. 1994 Aug;97 Suppl 2:1-3 PMID: 8070139
  16. Gestational age-dependent distribution of Escherichia coli fimbriae in pregnant patients with pyelonephritis.
    Ann N Y Acad Sci. 1994 Aug 15;730:290-1 PMID: 7915894
  17. dra-related X adhesins of gestational pyelonephritis-associated Escherichia coli recognize SCR-3 and SCR-4 domains of recombinant decay-accelerating factor.
    Infect Immun. 1995 May;63(5):1663-8 PMID: 7537246
  18. Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment.
    J Virol. 1995 Jun;69(6):3873-7 PMID: 7538177
  19. Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding.
    J Virol. 1995 Sep;69(9):5497-501 PMID: 7543583
  20. Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection.
    Microbiol Immunol. 1995;39(5):295-305 PMID: 7565169
  21. Virulence characteristics of Escherichia coli causing first urinary tract infection predict risk of second infection.
    J Infect Dis. 1995 Dec;172(6):1536-41 PMID: 7594713
  22. Human blood groups: incidental receptors for viruses and bacteria.
    Transfusion. 1996 Apr;36(4):362-74 PMID: 8623141
  23. Endocytosis of GPI-anchored proteins in human lymphocytes: role of glycolipid-based domains, actin cytoskeleton, and protein kinases.
    J Cell Biol. 1996 May;133(4):791-9 PMID: 8666664
  24. Molecular modeling and mechanism of action of human decay-accelerating factor.
    Protein Eng. 1996 Dec;9(12):1143-9 PMID: 9010927
  25. Development of experimental model of chronic pyelonephritis with Escherichia coli O75:K5:H-bearing Dr fimbriae: mutation in the dra region prevented tubulointerstitial nephritis.
    J Clin Invest. 1997 Apr 1;99(7):1662-72 PMID: 9120010
  26. Exploitation of mammalian host cell functions by bacterial pathogens.
    Science. 1997 May 2;276(5313):718-25 PMID: 9115192
  27. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry.
    J Virol. 1997 Jun;71(6):4736-43 PMID: 9151867
  28. Distribution of drb genes coding for Dr binding adhesins among uropathogenic and fecal Escherichia coli isolates and identification of new subtypes.
    Infect Immun. 1997 Jun;65(6):2011-8 PMID: 9169726
  29. Dr fimbriae operon of uropathogenic Escherichia coli mediate microtubule-dependent invasion to the HeLa epithelial cell line.
    J Infect Dis. 1997 Jul;176(1):158-67 PMID: 9207362
  30. Molecular cloning and characterization of Dr-II, a nonfimbrial adhesin-I-like adhesin isolated from gestational pyelonephritis-associated Escherichia coli that binds to decay-accelerating factor.
    Infect Immun. 1997 Oct;65(10):4309-18 PMID: 9317041
  31. Cell receptors for picornaviruses as determinants of cell tropism and pathogenesis.
    Trends Microbiol. 1998 May;6(5):198-202 PMID: 9614344
  32. Short consensus repeat domain 1 of decay-accelerating factor is required for enterovirus 70 binding.
    J Virol. 1998 Nov;72(11):9380-3 PMID: 9765493
  33. Viral cell entry induced by cross-linked decay-accelerating factor.
    J Virol. 1998 Nov;72(11):9407-12 PMID: 9765499
  34. Crystallization and preliminary X-ray diffraction analysis of a biologically active fragment of CD55.
    Acta Crystallogr D Biol Crystallogr. 1999 Jun;55(Pt 6):1198-200 PMID: 10329784
  35. Decay-accelerating factor and cytoskeleton redistribution pattern in HeLa cells infected with recombinant Escherichia coli strains expressing Dr family of adhesins.
    Infect Immun. 1999 Aug;67(8):3989-97 PMID: 10417165
  36. Molecular analysis and epidemiology of the Dr hemagglutinin of uropathogenic Escherichia coli.
    Infect Immun. 1989 Feb;57(2):446-51 PMID: 2643568
  37. The Dr hemagglutinin, afimbrial adhesins AFA-I and AFA-III, and F1845 fimbriae of uropathogenic and diarrhea-associated Escherichia coli belong to a family of hemagglutinins with Dr receptor recognition.
    Infect Immun. 1990 Jan;58(1):279-81 PMID: 1967170
  38. Recurring urinary tract infection: incidence and risk factors.
    Am J Public Health. 1990 Mar;80(3):331-3 PMID: 2305919
  39. Chronic enterovirus infection in patients with postviral fatigue syndrome.
    Lancet. 1988 Jan 23;1(8578):146-50 PMID: 2892990
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
Published
2000-03-00
Pages
1391-9
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC97293
Subset
IM
Grants
NIDCR NIH HHS · DE42029 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com